Navigation Links
Coherus Biosciences Invited to Present at 2014 J.P. Morgan Annual Healthcare Conference
Date:1/7/2014

REDWOOD CITY, Calif., Jan 7, 2014 /PRNewswire/ -- Denny Lanfear, President and CEO of Coherus Biosciences, will present at the J.P. Morgan 32nd Annual Healthcare Conference on Wednesday, January 15 at the Westin St. Francis in San Francisco, CA., beginning at 4:30pm Pacific Standard Time. 

(Logo:  http://photos.prnewswire.com/prnh/20120507/SF01448LOGO)

"Coherus' upcoming presentation at the conference marks an important milestone for our Company.  This event will introduce Coherus Biosciences to a worldwide healthcare investor audience and reflects the good progress the Company has made with products and partnerships," stated Mr. Lanfear. "To date, Coherus has filed INDs on three products and completed partnership agreements in Asia, Latin America and Europe with major biopharma firms while retaining US rights on all its products. We believe that this progress distinguishes Coherus as the leading independent pure play biosimilar company."

About Coherus Biosciences

Founded in 2010, Coherus Biosciences is a leading pure play biosimilar platform Company headquartered in the San Francisco Bay Area. Biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases. Our vision is to increase global patient access to high quality, life changing biologic medications.  Coherus' global partnerships include top tier BioPharma companies in Europe, Asia, and Latin America who are pursuing the integrated development and commercialization of products representing over $35 billion in current global sales.  From conceptualization to commercialization, Coherus' unique business model leverages a strategic consortium of key service providers aligned through ownership and shared incentives.  Through these partnerships, the Company has built a capital efficient infrastructure capable of taking products from cell lines to approved labels. To date, Coherus has raised approximately $125 million from equity and non-dilutive licensing fees.  Existing investors include KMG Capital, Lilly Ventures, Sofinnova and Venrock. 

Coherus Biosciences Contact
George Montgomery
(650) 649-3567
gmontgomery@coherus.com


'/>"/>
SOURCE Coherus BioSciences
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Coherus Announces CHS-0214 (Proposed Etanercept Biosimilar) Meets Primary Endpoint In Pivotal Pharmacokinetic Clinical Study
2. Coherus anuncia que CHS-0214 (biosimilar etanercept propuesto) supera punto final primario en decisivo estudio clínico farmacocinético
3. Coherus Biosciences als Präsentator zur J.P. Morgan Annual Healthcare Conference 2014 eingeladen
4. Pressure BioSciences, Inc. and Target Discovery, Inc. Expand Strategic License Agreement and Collaboration Supporting TDIs Planned Offering of Personalized Medicine Clinical Diagnostic Services
5. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2012 Financial Results
6. Amarantus BioSciences to Present at the New York Biotechnology Association (NYBA) 21st Annual Meeting on May 2nd, 2012
7. Neurocrine Biosciences Reports First Quarter 2012 Results
8. Pressure BioSciences, Inc. to Discuss First Quarter 2012 Financial Results And Provide Business Update
9. Ambit Biosciences and Teva Announce Clearance of an Investigational New Drug (IND) Application for CEP-32496, A Novel BRAF(V600E) Inhibitor
10. Neurocrine Biosciences to Present at the Jefferies 2012 Global Healthcare Conference
11. 3-V Biosciences To Present at the Seventh Annual JMP Securities Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... 9, 2016  Forge Therapeutics, Inc. today announced ... Exchange: EVT, TecDAX, ISIN: DE0005664809) to advance its ... treatment of bacterial infections including those caused by ... an attractive antibacterial target for more than the ... chemical starting points has hampered its progress. Forge ...
(Date:12/8/2016)... Australia Ophthalmic Lasers Market Outlook to 2022 ... Market Outlook to 2022", provides key market data on ... in millions of US dollars, volume (in units) and ... Femtosecond Lasers and YAG Lasers. The report also ... of these market segements, and global corporate-level profiles of ...
(Date:12/8/2016)... Dec. 8, 2016 KEY FINDINGS ... Patient warming ... of blood during surgeries, lowering the risks of neurological disorders ... of SSIs. The patient warming systems can be segmented into ... benefits in turn reduce the stay at hospitals thus, lowering ...
Breaking Medicine Technology:
(Date:12/8/2016)... and JENNERSVILLE, Pa. (PRWEB) , ... December 08, ... ... that Penn Medicine Southern Chester County, a Property owned by an affiliate of ... million, 72,000 square foot Penn Medicine Southern Chester County ambulatory care center (ACC) ...
(Date:12/8/2016)... ... ... With the increasing demand for dental implants, the National Association of Dental ... dentists and patients about the safety issues related to dental restorations. According to the ... is projected to reach $6.4 billion in 2018 with more than 30 million Americans ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... for customers and employees that are both engaging and easy to use. Coming ... Technology, the software company revealed today its plans to roll out new AI-powered ...
(Date:12/8/2016)... ... December 08, 2016 , ... STATEN ISLAND, N.Y., Nov. 24, ... to the highest standards of trauma, maternity, cancer and chronic obstructive pulmonary disease ... CEO, Dr. Daniel Messina. , Among the recognitions, the American College of Surgeons' ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... as possible. With this in mind, SIGVARIS has created a new line of ... during bed rest and provide the benefits of graduated compression when transitioning from ...
Breaking Medicine News(10 mins):